Table 1.
Characteristics of the study population
| pCR (%) | Non-pCR (%) | Whole population (%) | |
|---|---|---|---|
| N | 28 (25.0) | 84 (75.0) | 112 |
| Median age | 47.0 | 51.5 | 50.5 |
| IQR | 39.0–55.0 | 39.0–59.0 | 39.0–58.0 |
| Menopausal status [n (%)] | |||
| Premenopausal | 17 (60.7) | 41 (48.8) | 58 (51.8) |
| Postmenopausal | 11 (39.3) | 43 (51.2) | 54 (48.2) |
| Baseline clinical staging [n (%)] | |||
| Stage I | 1 (3.6) | 1 (1.2) | 2 (1.8) |
| Stage II | 13 (46.4) | 34 (40.5) | 47 (42.0) |
| Stage III | 14 (50.0) | 49 (58.3) | 63 (56.3) |
| Median overall NAC cycles (IQR) | 8.0–8.0 | 5.0–8.0 | 6.0–8.0 |
| NAC regimens [n (%)] | |||
| Anthracycline-and-Taxane-based | 25 (89.3) | 65 (77.4) | 90 (80.4) |
| Anthracycline-based only | 0 (0) | 8 (9.5) | 8 (7.1) |
| Taxane-based only | 3 (10.7) | 11 (13.1) | 14 (12.5) |
| Breast surgery | |||
| Breast conserving surgery | 5 (17.9) | 12 (14.3) | 17 (15.2) |
| Mastectomy | 23 (82.1) | 72 (85.7) | 95 (84.8) |
| Axillary surgery | |||
| SLNB | 5 (17.9) | 10 (11.9) | 15 (13.4) |
| ALND | 23 (82.1) | 74 (88.1) | 97 (86.6) |